CHRM1 and Dyskinesia: Indeed, blunting M1R or CDGI signaling in iSPNs not only attenuated the oscillations in dendritic excitability and synaptic strength, it also had clear behavioral effects – increasing the symptomatic benefit of levodopa and attenuating on-state dyskinesia.